Generate:Biomedicines is the first drug generation company pioneering a machine learning-powered generative biology platform with the ability to create new drugs on demand across a wide range of biologic modalities. The Generate Platform - which is a continuous loop to generate, build, measure, and learn - can drastically increase the speed at which targets and therapeutics are identified and validated. This will improve the specificity of target engagement by generated proteins and reduce the time and cost of identifying and developing clinical candidates.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/14/23 | $273,000,000 | Series C |
Abu Dhabi Investment Authority Amgen Ventures ARCH Venture Partners Fidelity Management & Research Company Flagship Pioneering MAPS Capital March Capital Partners NVentures Pictet T. Rowe Price Associates | undisclosed |
